Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary DataSrđan Verstovšek, Claire Harrison, Mohamed E. Salama et al.|Blood|2021Cited by 9
P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 InhibitorsTengfei Li, Mark A. Socinski, Yu Xiao et al.|Journal of Thoracic Oncology|2025Cited by 1
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trialByoung Chul Cho, Yi‐Long Wu, Rama Balaraman et al.|Nature Medicine|2026Cited by 0